These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2793372)

  • 21. [Phase I study of 5'-deoxy-5-fluorouridine (5'-DFUR)].
    Nakao I; Saito T; Kimura K; Wakui A; Yokoyama M; Kanamaru R; Furue H; Komita T; Ohta K; Murakami M
    Gan To Kagaku Ryoho; 1985 Oct; 12(10):2037-43. PubMed ID: 2932058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An EORTC phase II study of vindesine in advanced prostate cancer.
    Jones WG; Fosså SD; Denis L; Coninx P; Glashan RW; Akdas A; De Pauw M
    Eur J Cancer Clin Oncol; 1983 May; 19(5):583-8. PubMed ID: 6683629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of trimetrexate, an analog of methotrexate, administered monthly in the form of nine consecutive daily bolus injections.
    Jolivet J; Landry L; Pinard MF; McCormack JJ; Tong WP; Eisenhauer E
    Cancer Chemother Pharmacol; 1987; 20(2):169-72. PubMed ID: 2959389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer.
    Pelley R; Ganapathi R; Wood L; Rybicki L; McLain D; Budd GT; Peereboom D; Olencki T; Bukowski RM
    Cancer Chemother Pharmacol; 2000; 46(3):251-4. PubMed ID: 11021744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of high-dose cytosine arabinoside and etoposide in patients with advanced malignancies.
    Powell BL; Muss HB; Capizzi RL; Caponera ME; White DR; Zekan PJ; Atkins JN; Jackson DV; Richards F; Craig JB
    Cancer Chemother Pharmacol; 1987; 19(3):250-2. PubMed ID: 3581419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days.
    Stevenson JP; Sun W; Gallagher M; Johnson R; Vaughn D; Schuchter L; Algazy K; Hahn S; Enas N; Ellis D; Thornton D; O'Dwyer PJ
    Clin Cancer Res; 2002 Aug; 8(8):2524-9. PubMed ID: 12171879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase I study of menogaril in patients with advanced cancer.
    Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
    J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).
    Peek SF; Cote PJ; Jacob JR; Toshkov IA; Hornbuckle WE; Baldwin BH; Wells FV; Chu CK; Gerin JL; Tennant BC; Korba BE
    Hepatology; 2001 Jan; 33(1):254-66. PubMed ID: 11124844
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I--II study of N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
    Kimura K; Yamada K; Uzuka Y; Maekawa T; Takaku F; Shimoyama M; Ogawa M; Amaki I; Osamura S; Ito M; Sakai Y; Oguro M; Hattori K; Hoshino A; Hirota Y; Ohta K; Nakamura T; Masaoka T; Kimura I; Ichimaru M
    Recent Results Cancer Res; 1981; 76():232-40. PubMed ID: 7232852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.
    Sessa C; Minoia C; Ronchi A; Zucchetti M; Bauer J; Borner M; de Jong J; Pagani O; Renard J; Weil C; D'Incalci M
    Ann Oncol; 1998 Dec; 9(12):1315-22. PubMed ID: 9932162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase I trial of spirogermanium administered on a continuous infusion schedule.
    Woolley PV; Ahlgren JD; Byrne PJ; Priego VM; Schein PS
    Invest New Drugs; 1984; 2(3):305-9. PubMed ID: 6511236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy-beta-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells.
    Klecker RW; Katki AG; Collins JM
    Mol Pharmacol; 1994 Dec; 46(6):1204-9. PubMed ID: 7808443
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma.
    Lynch G; Currie V; Kemeny N
    Cancer Clin Trials; 1981; 4(3):281-3. PubMed ID: 6974612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
    Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I trial of teroxirone.
    Neidhart JA; Derocher D; Grever MR; Kraut EH; Malspeis L
    Cancer Treat Rep; 1984 Sep; 68(9):1115-9. PubMed ID: 6478450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of 2'-fluorinated arabinosyl-pyrimidine nucleosides on duck hepatitis B virus DNA level in serum and liver of chronically infected ducks.
    Fourel I; Li J; Hantz O; Jacquet C; Fox JJ; Trépo C
    J Med Virol; 1992 Jun; 37(2):122-6. PubMed ID: 1629711
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I evaluation of 773U82.HCl, a member of a new class of DNA intercalators.
    Havlin KA; Kuhn JG; Craig JB; Weiss GR; Koeller J; Turner JN; Luther JS; Clark G; Bair KW; Wargin W
    Anticancer Drugs; 1991 Aug; 2(4):357-63. PubMed ID: 1797191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracil.
    Balakrishna Pai S; Liu SH; Zhu YL; Chu CK; Cheng YC
    Antimicrob Agents Chemother; 1996 Feb; 40(2):380-6. PubMed ID: 8834884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study of carboplatin given on a five-day intravenous schedule.
    Rozencweig M; Nicaise C; Beer M; Crespeigne N; Van Rijmenant M; Lenaz L; Kenis Y
    J Clin Oncol; 1983 Oct; 1(10):621-6. PubMed ID: 6366128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.